The four pillars of our Commitment
Respecting and understanding the patient community perspective
Expanding access to our medicines
Conducting responsible clinical trials
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine.
40+
Patient organizations representing
200m
Patients contributed to its development
108 514
Novartis associates own it as an aspiration
The Novartis Commitment to Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
Patients and Caregivers COVID-19 Information
Disclosure of patient organization funding
Our Commitment – reporting 2021 progress
84%
Early research programs
in general medicines obtained patient insights before first-in-human trials (healthy volunteers). Piloted patient panels for five Proof of Concept indications.
8 092
Patients reached through managed access programs
95% requests approved for 62 compounds in 95 countries - providing pre-approval access to Novartis medicines. At the end of 2021, more than 13 000 patients were receiving treatment through MAPs.
57
Clinical development programs
comprising 70 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials.
89
Clinical trials
included Patient Reported Outcomes (PRO) conducted in 72 countries.
150
Simplified summaries
from Phase 1-4 clinical trials sent to investigators to share with 27 013 trial participants and posted on novartis.com/clinicaltrials.
56.2m
Patients
reached through access approaches.
Clinical Trials
About clinical trials
Clinical trials are scientific studies conducted to find better ways to prevent, screen for, diagnose or treat disease.
Participating in Novartis clinical trials
Novartis is currently conducting clinical trials around the world for a number of diseases.
Managed Access programs
Novartis Managed Access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.
Diversity
Diversity in clinical trials is integral to who we are at Novartis and we are working hard to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials. (PDF 0.2 MB)
Collaborations with Patient Organizations
Sound up for lung cancer research
Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
Novartis ranks #4 in PatientView’s 2019 corporate reputation survey of patient organizations worldwide
Patient Organizations and Novartis
External Funding
Patient Perspectives
For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.